TrialClinical and translational science2021

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction.

Karin Nelander et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.